2Silber S,Albertsson P,Avils FF,et al. Guidelines for percuta neous coronary interventions The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology[J]. Eur Heart J,2005,26(8) 804 - 806.
6Beeres SL,Oemrawsingh PV, Warda H M, et al. Early admin istration of abciximab in patients with acute myocardial infarction improves angiographic and clinical outcome after primary angioplasty[J]. Catheter Cardiovasc Interv, 2005, 65 478 - 483.
6[6]Peerlinck K,De Lepeleire I,Goldberg M,et al.MK-383(L700462),a selective nonpeptide platelet glycoprotein Ⅱ b/Ⅲ a antagonist,it active in m an.Circulation,1993,88:1512-1517.
7[7]McClellan KG,Goa KL.Tiroflban:A review of its use in acute coronary syndrome.Drugs,1998,56:1067-1080.
8[7]Boersma E,Harrington RA,Moliterno DJ,et al.Platelet glycoprotein Ⅱ b/Ⅲ a inhibitors in acute corony syndromes:a meteanalysis of all major randomized clinical trials.Lmmet,2002,359:189-198.
9[9]Montalescot G,Choussat R.Collet JP.Glycoprotein Ⅱ b/Ⅲ a receptorB and pfimary stenting in acute myocardial infarction.Eur Heart J,2001,3(Suppl A):S3-S7.
10[10]Montalescot G,Borentain M,Payot L,et al.Early vs late administration of glyeoprotein Ⅱ b/Ⅲa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction:a mete-analysis.JAMA,2004,292:362-366
